Cardiovascular Biologics and Cell Therapy Markets Project Strong Growth Through 2033

The global cardiovascular biologics market was valued at $2.20 billion in 2024 and is projected to reach $4.23 billion by 2033, growing at a compound annual growth rate of 7.5% during the forecast period 2025-2033. The market is witnessing rapid expansion driven by advancements in RNA-based therapies and biologic innovations that enable precise targeting of cardiovascular disease mechanisms.

Biologics, including recombinant proteins, monoclonal antibodies, and gene-modulating RNA therapeutics such as siRNA and mRNA, offer new and more effective approaches to modulating inflammatory, thrombotic, and lipid pathways. These biologics deliver long-lasting therapeutic outcomes, reduced side effects, and improved efficacy compared to conventional cardiovascular drugs.

Key breakthroughs in PCSK9, IL-6, and TTR pathways are transforming cardiovascular disease management, enabling the development of next-generation biologics that address hypercholesterolemia, atherosclerosis, heart failure, and amyloidosis. The success of therapies targeting these mechanisms such as PCSK9 inhibitors and TTR stabilizers has paved the way for expanded clinical applications and multiple late-stage pipeline candidates.

In July 2025, Novartis announced that the FDA had approved a label update for Leqvio (inclisiran), allowing its use as a monotherapy alongside diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, marking its expansion as a first-line PCSK9-targeting cardiovascular biologic therapy.

In October 2025, Ionis Pharmaceuticals, in collaboration with Novartis, received FDA approval for pelacarsen, an antisense oligonucleotide therapy designed to lower lipoprotein(a) [Lp(a)] levels, marking a major milestone in addressing genetically driven cardiovascular risk factors.

In January 2026, Amgen Inc. announced positive Phase III clinical results for its next-generation PCSK9 inhibitor, demonstrating significant LDL cholesterol reduction and improved cardiovascular outcomes in high-risk patients compared to existing monoclonal antibody therapies.

In December 2025, AstraZeneca entered a strategic research partnership with Silence Therapeutics to co-develop siRNA-based therapeutics targeting novel genetic pathways implicated in atherosclerosis and heart failure, expanding its RNA-based cardiovascular drug portfolio.

In August 2025, Pfizer Inc. launched its first RNA-based biologic for transthyretin amyloidosis (ATTR-CM) in Japan following regulatory approval, expanding patient access to gene-silencing therapies for rare cardiovascular diseases.

In June 2025, Bristol Myers Squibb acquired Cardio Therapeutics, a biotech company specializing in IL-6-targeted biologics for inflammatory cardiovascular conditions, strengthening its immuno-cardiology portfolio.

In August 2025, Roche and Alnylam Pharmaceuticals advanced zilebesiran an investigational RNAi therapeutic into a global Phase III cardiovascular outcomes trial to evaluate its potential in reducing major adverse cardiovascular events in patients with uncontrolled hypertension. This milestone underscores the growing clinical momentum in RNA-based cardiovascular drug development and highlights the sector's shift toward next-generation biologic modalities.

Key players in the cardiovascular biologics market include Regeneron Pharmaceuticals, Inc., Amgen Inc., Novartis Pharmaceuticals Corporation, Alnylam Pharmaceuticals, Inc., Genentech USA, Inc., Reliance Life Sciences, Biocon Biologics Limited, and Shanghai Junshi Biosciences Co.

The cell therapy market is estimated to be valued at $2,832.1 million in 2025 and is expected to reach $5,383.4 million by 2032, growing at a compound annual growth rate of 9.6% from 2025 to 2032. The growth of the cell therapy market is primarily driven by a combination of evolving consumer demand, technological advancements, and favorable regulatory frameworks. Increasing awareness and adoption across diverse industries have accelerated market expansion, while continuous product innovation and strategic partnerships are enhancing competitive dynamics.

Key players in the cell therapy market include Bristol Myers Squibb Company, Amgen Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Services Inc., Allogene Therapeutics, Athersys Inc., Orchard Therapeutics, JW Therapeutics Co. Ltd., Dendreon Pharmaceuticals LLC., Autolus Therapeutics, APAC Biotech, CORESTEM, Inc., BioCardia, Inc., JCR Pharmaceuticals Co., Ltd., Oxford Biomedica, and CASI Pharmaceuticals Inc.

The global market for oligonucleotides was valued at $9.1 billion in 2025 and is estimated to reach $15.7 billion by 2030, at a compound annual growth rate of 11.5% from 2025 through 2030. The use of oligonucleotides as therapeutic and diagnostic agents is an emerging field of study. Antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA), aptamers and DNAzymes are used in the treatment of various diseases.

Alnylam Pharmaceuticals Inc. is a leading company in the oligonucleotides market, with many approved products in strategic therapeutic areas, including genetic medicine, cardio-metabolic disease, infectious disease and central nervous system (CNS) and ocular diseases. Other key companies in the market include Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc. and Jazz Pharmaceuticals. In addition to therapeutics, oligonucleotide technology is also applied in diagnostics and research.